Form 4: BioLife Solutions Executive Sells Shares Under 10b5-1 Plan

Karen A. Foster, Chief Quality and Operations Officer at BioLife Solutions, sold 66 shares of common stock at $26.34 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Karen A. Foster, Chief Quality and Operations Officer at BioLife Solutions, sold 66 shares of the company's common stock.
• The transaction occurred on November 12, 2024, at a price of $26.34 per share.
• The sale was executed under a pre-existing Rule 10b5-1 trading plan adopted on February 8, 2021.
• This plan was established to cover tax withholding obligations related to the vesting of restricted stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged trading plan, with no indication of positive or negative sentiment.

Industry Context

This is a routine transaction for executives who have pre-arranged trading plans to manage their stock holdings and tax obligations. It is common for executives to use 10b5-1 plans to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the biotechnology and life sciences sectors, such as Thermo Fisher Scientific and Danaher Corporation.
• These plans allow executives to sell shares at predetermined times and prices, mitigating the risk of insider trading allegations.
• The reported transaction is consistent with standard practices for executives managing their equity compensation.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on shareholder sentiment, but is unlikely to have a significant effect due to the pre-arranged nature of the transaction.

Key Dates

Keywords

BioLife Solutions, BLFS, insider trading, Form 4, 10b5-1 plan, stock sale, executive, Karen A. Foster, Chief Quality and Operations Officer